Johnson & Johnson
JNJ · Healthcare
$271.19
Indlæser diagram…
Nyheder
Seneste overskrifter for denne aktie
Intuitive Surgical's Growth Has Cooled From Its Post-Pandemic Highs. Is That a Buying Opportunity or a Warning?
Intuitive Surgical's stock has declined 40% from recent highs amid slowing da Vinci robot sales growth due to increased competition from Medtronic and Johnson & Johnson. However, the company's core business model relies on recurring revenue from parts and services (75% of revenue), which provides stable annuity-like income streams. With valuation metrics below five-year averages and continued AI opportunities, the stock may represent a buying opportunity for aggressive growth investors despite its historical volatility.
Atopic Dermatitis Drugs Market Set to Reach USD 33.42 Billion by 2035, at a CAGR of 7.70% - SNS Insider
The global atopic dermatitis drugs market is projected to grow from USD 15.92 billion in 2025 to USD 33.42 billion by 2035, driven by increased adoption of biologic therapies, JAK inhibitors, and novel treatments. North America leads with 36% market share, while Asia-Pacific shows the fastest growth. Biologics dominate with 42% market share, though high costs and JAK inhibitor safety warnings present challenges.
Renal Denervation Market Size, Share & Trends Analysis - Global Opportunity Analysis and Industry Forecast (2026-2036)
The global renal denervation market is expected to experience significant growth driven by rising resistant hypertension cases, positive clinical trial results, regulatory approvals, and technological advances in radiofrequency, ultrasound, and micro-infusion technologies. North America currently leads the market while Asia-Pacific is projected to grow fastest. The minimally invasive procedure treats uncontrolled hypertension by disrupting sympathetic nerves surrounding renal arteries.
2 Absurdly Cheap Dividend Stocks to Buy With $1,000 Right Now
Bristol Myers Squibb and Pfizer are recommended as undervalued pharmaceutical stocks offering above-average dividend yields. BMY offers a safer 3.76% yield with a sustainable 45% FCF payout ratio and growing oncology portfolio, while PFE provides a higher 6.04% yield but with a riskier 89% payout ratio. Both trade at steep discounts to peers despite facing patent expiration challenges.
Healthcare ETF Comparison: Fidelity's FHLC vs. Invesco's Biotech-Focused IBBQ
Fidelity's FHLC and Invesco's IBBQ offer different healthcare investment strategies. FHLC provides broad exposure to 365 healthcare holdings with a lower 0.08% expense ratio and 1.2% dividend yield, while IBBQ focuses on biotech with higher volatility, delivering 56.4% 1-year returns but experiencing a 37.9% maximum drawdown. The choice depends on investor risk tolerance and diversification preferences.